Copyright © 2018 UCSD ADRC.
All rights reserved.

Neurology Staff

James B. Brewer, MD, PhD James B. Brewer, MD, PhD Director of the Shiley-Marocs ADRC. Professor of Neurosciences. Joined the ADRC in 2004. Medical Degree: Stanford University and his neurology residency training at Johns Hopkins University. He joined the Department of Neurosciences in 2004, in a joint recruitment of the Departments of Neurosciences and Radiology, and is a leading investigator at the interdisciplinary Multimodal Imaging Laboratory. Field of interest: Structural and functional brain changes in early Alzheimer’s disease.
Mohammed Ahmed, MD

Mohammed Ahmed, MD joined the Shiley-Marcos ADRC team to as a part of his fellowship training in Behavioral Neurology. Dr Ahmed is faculty with the Department of Neurosciences, and also a diplomate of the American Board of Psychiatry and Neurology. Dr Ahmed specializes in treating people with various neurodegenerative disorders such as alzheimer's disease, fronto-temporal dementia, lewy body dementia, as well as Traumatic Brain Injury (TBI)/ Concussions. Dr Ahmed’s clinical and research interest is to understand the link between concussion and neurodegenerative process such at CTE, Alzheimer’s.  Here at the ADRC, he performs neurological examinations, investigator for clinical trials, and participates in scholarly activities.

Jody Corey-Bloom MD, PhD Jody Corey-Bloom MD, PhD Clinical Professor, Department of Neurosciences. Joined the ADRC in 1990. Medical Degree: 1986 UCSD School of Medicine, La Jolla, CA. Field of Interest: clinical research pertaining to Alzheimer’s disease and neurological disorders in the elderly.
Dr. Howard Feldman

Dr. Howard Feldman is a neurologist with special expertise in cognitive disorders and the dementias. He is Professor in the Department of Neurosciences, at the University of California, San Diego and Director of the Alzheimer Disease Cooperative Study (from April 1, 2016). He holds an affiliate appointment at the University of British Columbia, where he has as served Director of the Clinic for Alzheimer’s Disease and Related Disorder, and as the inaugural Fisher Family, and Alzheimer Society of British Columbia Endowed Professorship for Alzheimer’s disease research. He has authored or coauthored over 160 peer reviewed publications among total publications of > 390 and has H Index > 50. His career contributions have been profiled in Lancet Neurology in 2007, and in 2014 he was named by Thomson Reuters as a ‘highly cited’ neuroscientist (2002-2012) and among ‘the world’s most influential scientific minds’. He has been appointed as Fellow of the Canadian Academy of Health Sciences and the American Academy of Neurology in 2008.

Douglas R. Galasko, MD Douglas R. Galasko, MD Co-Director of the Shiley-Marcos ADRC Clinical Core. Professor In Residence, Department of Neurosciences. Joined the ADRC in 1987. Medical Degree: 1979 Johannesburg General Hospital, Johannesburg, South Africa. Fielpxd of interest: Clinical research pertaining to Alzheimer’s disease and neurological problems associated with aging.
Gabriel Léger

Doctor Gabriel Léger completed his training in clinical neurology at the Montreal Neurological Institute of McGill University, where he also performed research in imaging of neurodegenerative diseases. He completed clinical fellowships in Movement Disorders at McGill, and in Cognitive and Behavioral Neurology at Northwestern University, Chicago.   He returned to Montreal, where he was Assistant Professor and Director of the Neurology Residency program at the University of Montreal.  In 2011, he moved to the Lou Ruvo Center for Brain Health of the Cleveland Clinic, Las Vegas, where he directed their fellowship program in Behavioral Neurology and Neuropsychiatry and their FTD and young-onset dementia clinic.  He has participated in numerous clinical trials targeting the diagnosis and treatment of Alzheimer’s disease and related disorders. In addition, he has special interests and expertise in the diagnosis and treatment of atypical and focal dementias, including frontotemporal dementia (FTD or Pick’s disease), Primary Progressive Aphasia, Posterior Cortical Atrophy, and dementias with Lewy bodies.  He joined the neurosciences faculty at UCSD and the ADRC in July 2018.

Roberto Malinow, MD, PhDRoberto Malinow, MD, PhD Professor of neurosciences. Malinow came to the UC San Diego School of Medicine in March 2008 from Cold Spring Harbor Laboratory, a private, non-profit research institution in New York, where he held the Alle Davis and Maxine Harrison Endowed Chair of Neurosciences since 1998.  His research focuses on synaptic transmission and plasticity, learning and memory.   He received his medical degree from New York University and his Ph.D. degree from UC Berkeley. Malinow has received numerous awards including the MetLife Foundation Award for Medical Research and has been keynote speaker in several venues including the Einar Hille Memorial Lecture, KAC Elliot Lecture and Gordon Conference on Synaptic Transmission.
Kristoffer Nissinen, MDKristoffer Nissinen, MD was born in San Diego, CA and in his first years moved to Finland where he spent the first 20 years of his life. He moved back to the United States in 2001 to pursue a degree in medicine. He completed his undergraduate studies in Biological Sciences at UCI after which he moved to Arkansas for medication school and obtained his MD from the University of Arkansas for Medical Sciences School of Medicine. He completed his neurology residency at UCI Medical Center and Long Beach VA in the spring of 2011. He is currently furthering his training at the ADRC as a Neurology Fellow with focus on memory disorders and neurodegenerative diseases which includes working with patient’s in clinical practice and clinical trials.
Mark Tuszynski, MD, PhD Mark Tuszynski, MD, PhD Professor of Neurosciences. Joined the ADRC in 1991. Medical Degree: 1983 University of Minnesota, Minneapolis, MN. Field of Interest: trophic factor effects on neurons in animal models of Alzheimer’s disease, clinical trials of cholinergic agonists in Alzheimer’s disease, gene therapy, nervous system growth factors, and spinal cord injury.